Reata Pharmaceuticals

$117.09
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.20 (+0.17%) As of 1:39 PM EDT today

Why Robinhood?

You can buy or sell RETA and other stocks, options, and ETFs commission-free!

About RETA

Reata Pharmaceuticals, Inc. Class A Common Stock, also called Reata Pharmaceuticals, is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Read More Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by W. Christian Wigley, Waldemar Priebe, Philip J. Thomas, Jef Karel de Brabander, Thomas C. Südhof, Jonathan M. Graff and J. Warren Huff on September 1, 2002 and is headquartered in Irving, TX. The listed name for RETA is Reata Pharmaceuticals, Inc. Class A Common Stock.

CEO
J. Warren Huff
Employees
220
Headquarters
Plano, Texas
Founded
2002
Market Cap
3.95B
Price-Earnings Ratio
Dividend Yield
Average Volume
163.47K
High Today
$117.55
Low Today
$113.46
Open Price
$116.33
Volume
65.24K
52 Week High
$257.97
52 Week Low
$88.17

Collections

RETA Earnings

-$3.67
-$2.45
-$1.22
$0.00
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Estimated
per share
Actual
Expected Nov 9, Pre-Market

You May Also Like